PMID- 24183259
OWN - NLM
STAT- MEDLINE
DCOM- 20141014
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 102
IP  - 3
DP  - 2013 Dec
TI  - Effect of gender on treatment outcomes in type 2 diabetes mellitus.
PG  - 167-74
LID - S0168-8227(13)00343-4 [pii]
LID - 10.1016/j.diabres.2013.10.001 [doi]
AB  - AIM: To evaluate the effect of gender on clinical outcomes in people with type 2 
      diabetes mellitus (T2DM) receiving antidiabetes therapy. METHODS: This is a 
      pooled analysis from nine similarly designed phase 3 and 4 randomized, controlled 
      studies evaluating insulin glargine and an active comparator (NPH insulin, 
      insulin lispro, premixed insulin, oral antidiabetes drugs, dietary intervention) 
      in adults with T2DM. Impact of gender on outcomes including HbA1c, fasting plasma 
      glucose (FPG), weight-adjusted insulin dose, and hypoglycemia incidence was 
      evaluated after 24 weeks of treatment. RESULTS: Overall, 1651 male and 1287 
      female individuals were included; 49.8% and 50.2% were treated with insulin 
      glargine or comparators, respectively. Females receiving insulin glargine were 
      less likely than males to achieve a glycemic target of HbA1c</=7.0% (53mmol/mol) 
      (54.3% vs 60.8%, respectively, p=0.0162); there was no difference between females 
      and males receiving comparators (52.7% vs 51.3%, respectively, p=0.4625). Females 
      had significantly greater reductions in FPG (3.1mg/dL, p=0.0458), required 
      significantly higher insulin doses (0.03IU/kg, p=0.0071), and had significantly 
      higher annual rates of symptomatic (p<0.0001), glucose-confirmed (<50 and 
      <70mg/dL) symptomatic (p=0.0005 and p<0.0001), and severe hypoglycemia (p=0.0020) 
      than males. CONCLUSIONS: Females in this analysis had smaller reductions in HbA1c 
      and were less likely to reach glycemic goals despite higher insulin doses and 
      more hypoglycemic events than males. Differences in gender responses to therapy 
      should be considered when individualizing treatment for people with T2DM.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - McGill, J B
AU  - McGill JB
AD  - Washington University School of Medicine, St. Louis, MO, USA. Electronic address: 
      jmcgill@dom.wustl.edu.
FAU - Vlajnic, A
AU  - Vlajnic A
FAU - Knutsen, P G
AU  - Knutsen PG
FAU - Recklein, C
AU  - Recklein C
FAU - Rimler, M
AU  - Rimler M
FAU - Fisher, S J
AU  - Fisher SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131008
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Blood Glucose/analysis
MH  - Body Weight/drug effects
MH  - Clinical Trials, Phase III as Topic
MH  - Clinical Trials, Phase IV as Topic
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Sex Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Gender
OT  - Glycemic control
OT  - Hypoglycemia
OT  - Insulin glargine
OT  - Type 2 diabetes mellitus
EDAT- 2013/11/05 06:00
MHDA- 2014/10/15 06:00
CRDT- 2013/11/05 06:00
PHST- 2013/02/05 00:00 [received]
PHST- 2013/07/30 00:00 [revised]
PHST- 2013/10/01 00:00 [accepted]
PHST- 2013/11/05 06:00 [entrez]
PHST- 2013/11/05 06:00 [pubmed]
PHST- 2014/10/15 06:00 [medline]
AID - S0168-8227(13)00343-4 [pii]
AID - 10.1016/j.diabres.2013.10.001 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Dec;102(3):167-74. doi: 
      10.1016/j.diabres.2013.10.001. Epub 2013 Oct 8.